Syfovre Retinal Vasculitis Eye Inflammation Side Effects Causing Vision Loss
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
We are currently investigating Syfovre retinal vasculitis eye inflammation cases as possible Syfovre drug injury lawsuits for patients. These lawsuits would be against Apellis Pharmaceuticals, Inc., the drug company responsible for Syfovre.
Syfovre is an eye-injection drug treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). It was approved by the FDA on February 17, 2023.
Syfovre side effects include occlusive retinal vasculitis, which is a type of eye inflammation that blocks blood flow to the retina resulting in vision loss and could potentially cause blindness. There have also been reported cases of non-occlusive retinal vasculitis and other types of eye inflammation.
To date, all reported Syfovre adverse events causing these vision problems began one to two weeks after a patient’s first Syfovre injection.
Free Syfovre Case Evaluation
We encourage you to submit a Syfovre Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible Syfovre drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his more than 20 years of experience handling drug injury cases.
Most Recent Article About Syfovre
Syfovre Legal Compensation Cases for Retinal Vasculitis
Syfovre legal compensation cases for retinal vasculitis diagnosed after a patient’s first Syfovre injection are being filed as drug injury lawsuits. The basis for these product liability Syfovre lawsuits is the drug company Apellis Pharmaceuticals failed to warn about retinal vasculitis as a side effect until it revised the Syfovre drug label in November 2023.
The FDA approved Syfovre (pegcetacoplan) as an eye injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in February 2023.
The American Society of Retina Specialists (ASRS), published a general report on Syfovre retinal-related vision loss, co-authored by the ASRS Research and Safety in Therapeutics (ReST) Committee in December 2023. Their report revealed that at least 13 patients had developed Syfovre retinal-related vision loss earlier in 2023. Specifically, those 13 patients developed retinal vasculitis after their first Syfovre injection.
As mentioned previously, while Syfovre was initially available for use in February 2023, it was not until November 2023 that Apellis added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections to the Syfovre drug label. This time-lapse is a central part of the Syfovre legal compensation cases that are being filed.
In more detail, Syfovre injection side effects include occlusive retinal vasculitis and non-occlusive retinal vasculitis. These types of eye inflammation result in vision loss and potentially cause blindness.
To read more of this article, click below:
From this July 19, 2024 news report, “The Syfovre Balancing Act. The Retinal Vasculitis Risk Is Real But Research Also Points to Benefits | ASRS 2024“, we get the most recent findings about patients who were treated with Syfovre and then diagnosed with retinal vasculitis: “The combined results of two real-world evidence studies presented Thursday put the risk of developing retinal vasculitis at about 1 in every 1,330 patients.”
We are handling Syfovre legal compensation cases for retinal vasculitis diagnosed after a patient’s first Syfovre injection. These personal injury cases are drug injury lawsuits filed against Apellis Pharmaceuticals. More precisely, these Syfovre lawsuits are based on product liability law for the alleged failure to warn about retinal vasculitis as a Syfovre side effect promptly. As such, these Syfovre lawsuits are not filed against the patients’ eye doctors.
We have a free online Case Evaluation for these Syfovre legal compensation cases, or you can call us toll-free at 800-426-9535.
[Read the article in full at source]Earlier articles about Syfovre by attorney Tom Lamb on the Side Effects Blog:
- Syfovre’s Risks Keep It Off The Market In Europe, Again, With June 2024 Decision
- Syfovre: Loss of Vision 11 Days After Receiving Syfovre Injection
- Syfovre Eye Injury Cases Update One Year After First Reports: “Uncertain”
- At Least 13 Patients Had Syfovre Retinal-Related Vision Loss in 2023
- Syfovre Side Effects Issue Raised In December 2023 JAMA Viewpoint Piece
- New Syfovre Warnings for Retinal Vascular Occlusion and Retinal Vasculitis
- Syfovre Eye Side Effects Cases Reported at Ophthalmology Meeting
- Syfovre Retinal Vasculitis Cases Caused by Injection Kits With a 19-gauge Filter Needle?
- Syfovre Eye Injections Adverse Reactions Update August 2023
- Syfovre Vision Loss Cases Reported In Patients After First Injection